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CONCISE REPORT
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associated with cardiovascular events, disease activity, and
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Background: Asymmetric dimethylarginine (ADMA) is an
endogenous nitric oxide inhibitor and a new independent
risk factor for endothelial dysfunction and cardiovascular
disease.
Objective: To investigate the relationship between plasma
ADMA levels and cardiovascular events (CVEs) and disease
characteristics in patients with systemic lupus erythematosus
(SLE).
Methods: Demographic and clinical data were collected and
plasma ADMA levels were measured in 107 patients with
SLE. A modified organ damage index was calculated as
defined by the Systemic Lupus International Collaborating
Clinics/American College of Rheumatology Damage Index
(SDI), excluding CVE as an item.
Results: Cardiovascular disease, defined as >1 previous
arterial CVE, was recorded in 16/107 (15%) patients with
SLE and increased across tertiles of ADMA levels (p = 0.023
for trend). Mean plasma ADMA levels were significantly
higher in patients with SLE with a history of CVEs than in
patients without a CVE history (p = 0.018). In multiple
regression analysis a high SLEDAI score, high modified
SDI, high titre of anti-dsDNA antibodies, and low serum HDL
were significantly associated with high plasma ADMA levels.
Conclusion: In patients with SLE, plasma ADMA levels are
significantly associated with CVEs, measures of disease
activity, and organ damage, independently of an unfavour-
able lipid profile.
C
ardiovascular disease, including coronary heart dis-
ease,1 ischaemic cerebrovascular disease,2 and periph-
eral vascular disease3 has been recognised as an
important cause of morbidity and mortality in patients with
systemic lupus erythematosus (SLE). The mechanisms
underlying the accelerated atherosclerosis in SLE are not
completely clear because the traditional risk factors fail to
account fully for the excess of cardiovascular events (CVEs)
in lupus patients.4
Asymmetric dimethylarginine (ADMA) is an endogenous
inhibitor of nitric oxide synthase5 and is associated with
endothelial dysfunction.6 Furthermore, high ADMA plasma
levels are a risk factor for acute coronary events7 and a
predictor of mortality and CVEs in patients with end stage
renal disease.8
In the presence of anti-dsDNA, up regulation of methyla-
tion of arginine residues in proteins has been demonstrated
in vitro.9 As ADMA is released upon proteolysis of methylated
proteins,5 anti-dsDNA antibodies may be a trigger for
enhanced ADMA production in SLE. However, this has not
been studied in vivo.
This study aimed at assessing the hypothesis that plasma
ADMA levels are associated with CVEs in patients with SLE,
and with the presence of anti-dsDNA and other lupus
characteristics.
METHODS
Data collection and clinical measures
One hundred and seven consecutive patients fulfilling the
revised criteria for the classification of SLE were included.
The local ethics committee approved the study. All patients
provided informed consent. Demographic and clinical char-
acteristics were systematically documented by questionnaire,
chart review, and clinical examination. Data collection
comprised documented previous arterial CVEs. Coronary
artery events were defined as myocardial infarction, coronary
artery by-pass surgery, coronary angioplasty/stenting, and
angina pectoris. Ischaemic cerebrovascular events were
defined as transient ischaemic attacks, ischaemic stroke, or
carotid endarterectomy. Peripheral artery events were defined
as peripheral grafting or symptomatic peripheral artery
ischaemia, confirmed by angiography. Disease activity was
measured by the SLE Disease Activity Index (SLEDAI) and
European Consensus Lupus Activity Measure (ECLAM). A
modified organ damage index was calculated as defined by
the Systemic Lupus International Collaborating Clinics/
American College of Rheumatology Damage Index (SDI),
excluding CVEs as a damage item.
Biochemical measurements
ADMA was measured by high performance liquid chromato-
graphy, as published previously.10 The upper limit of the
reference range is 0.55 mmol/l. The subjects had fasted and
had refrained from smoking and alcohol consumption for at
least 24 hours before sampling. Laboratory investigations at
the time of ADMA measurement included C reactive protein,
serum creatinine, immunological measures, and fasting
levels of blood glucose, plasma homocysteine, serum total
cholesterol, high density lipoprotein cholesterol and trigly-
cerides. Anti-dsDNA titres were evaluated using an indirect
immune fluorescence technique with Crithidia luciliae as
Abbreviations: ADMA, asymmetric dimethylarginine; CVE,
cardiovascular event; DDAH, dimethylarginine-
dimethylaminohydrolase; hnRNP, heterogeneous nuclear
ribonucleoprotein; PRMT, protein arginine methyltransferase; SDI,
Systemic Lupus International Collaborating Clinics/American College of
Rheumatology Damage Index; SLE, systemic lupus erythematosus;
SLEDAI, SLE Disease Activity Index
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substrate. If the qualitative test in 1:10 dilution was positive,
titres were measured.
Statistical analyses
ADMA levels in patients with SLE with and without a history
of previous CVEs were compared using the non-parametric
(Mann-Whitney) test. Associations between ADMA levels
and clinical and other biochemical variables were identified
by univariate tests and subsequently by multiple regression
analyses. To determine which variables were independently
associated with ADMA levels, the variables with p,0.2 in the
univariate analyses and variables with supposed clinical
relevance were used as potential independent variables in a
stepwise multiple regression analysis with ADMA as depen-
dent variable. The stability of the model was checked by
tentatively adding to the (almost) final model single variables
initially not included in the model, in order to check once
more whether these variables could indeed be missed.
Statistical analysis was performed using SPSS 11.0 (SPSS
Inc, Chicago, IL). A two sided value of p,0.05 was considered
significant.
RESULTS
Table 1 shows the characteristics of the 107 patients with
SLE. At least one previous arterial CVE was documented in
16/107 (15%) patients. Coronary artery events had occurred
in seven (7%), ischaemic cerebrovascular events in 10 (9%),
and peripheral artery disease in four (4%) of the patients.
Association between plasma ADMA levels and
previous CVE
The mean (SD) plasma ADMA level (0.48 (0.07) mmol/l) in
patients with SLE with a history of CVE was significantly
higher than in patients with SLE without a history of CVE
Table 1 Demographic and clinical variables
and potential risk factors for arterial
cardiovascular disease*
Variables
All patients with
SLE
(n = 107)
Demographic variables
Female sex (%) 92
Age (years) 41 (13)
White (%) 76
Clinical variables
Disease duration (years) 6.7 (6.7)
SLEDAI 4.9 (4.1)
ECLAM 3.1 (1.7)
SDI (modified) 1.3 (1.7)
Corticosteroid use ever (%) 81
Current corticosteroid use (%) 52
Duration of corticosteroid use (months) 62 (69)
Current daily prednisone dose (mg) 13 (12)
Hydroxychloroquine use ever (%) 87
ESR (mm/1st h) 25 (24)
CRP (mg/l) 11 (16)
Serum creatinine (mmol/l) 88 (20)
Creatinine clearance (ml/min) 88 (26)
Anti-dsDNA (IE/ml) 34 (67)
Potential risk factors for arterial cardiovascular disease
BMI (kg/m2) 25 (6)
Current smoker (%) 22
Ever smoker (%) 54
Hypertension (%) 31
Diabetes (%) 8
Serum HDL cholesterol (mmol/l) 1.44 (0.37)
Serum LDL cholesterol (mmol/l) 2.8 (1.0)
Serum triglycerides (mmol/l) 1.25 (0.65)
Serum homocysteine (mmol/l) 11.7 (4.4)
Plasma ADMA (mmol/l) 0.44 (0.08)
*Except where indicated otherwise, values are the mean
(SD).
SLEDAI, Systemic Lupus Erythematosus Disease Activity
Index; ECLAM, European Consensus Lupus Activity
Measurement; SDI, Systemic Lupus International
Collaborating Clinics/American College of Rheumatology
Damage Index; ESR, erythrocyte sedimentation rate, normal
,10 mm/1st h; CRP, C reactive protein, normal ,8 mg/l;
serum creatinine, normal 60–110 mmol/l; creatinine
clearance, (1402age (years))6 body weight (kg)/(serum
creatinine (mmol/l)6R), for men R =0.86 and for women
R =1.01; BMI, body mass index; hypertension: defined by a
physician diagnosis and/or treatment with anti-hypertensive
drugs; diabetes: defined by a physician diagnosis and/or
the use of anti-diabetic drugs; LDL cholesterol, total
cholesterol—HDL cholesterol—(0.456triglycerides); ADMA,
asymmetric dimethylarginine.
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Figure 1 The percentage of patients with SLE with previous arterial
CVEs increases across the tertiles of plasma ADMA levels (p = 0.023 for
trend). In the lowest tertile (plasma ADMA levels (0.41 mmol/l) 2/36
(6%) patients had had a previous CVE, in the middle tertile (plasma
ADMA levels range 0.42–0.47 mmol/l) 5/35 (14%) and in the highest
tertile (plasma ADMA levels .0.47 mmol/l) 9/36 (25%) patients had
had a previous CVE.
Table 2 Univariate analyses of variables possibly
associated with plasma ADMA levels
Variables B SE p Value
CRP (mg/l) 0.0017 0.0010 0.001
Serum HDL (mmol/l) 20.0670 0.0220 0.003
Serum triglycerides (mmol/l) 0.0290 0.0130 0.027
Serum total cholesterol (mmol/l) 0.0061 0.0070 0.381
Plasma homocysteine (mmol/l) 0.0021 0.0020 0.284
Proteinuria 0.0910 0.0230 ,0.001
Creatinine clearance (ml/min) 20.0003 0.0001 0.323
Titre of anti-dsDNA (IE/ml) 0.0006 0.0001 ,0.001
Complement C3 (g/l) 20.0346 0.0280 0.226
Complement C4 (g/l) 20.1620 0.1360 0.237
Lupus anticoagulant 0.0437 0.0200 0.032
IgM anticardiolipin 0.0002 0.0450 0.997
IgG anticardiolipin 0.0031 0.0210 0.885
SLEDAI 0.0108 0.0020 ,0.001
ECLAM 0.0218 0.0050 ,0.001
SDI (modified) 0.0125 0.0050 0.010
Age (years) 0.0009 0.0010 0.140
Current smoking 20.0037 0.0110 0.734
Diabetes mellitus 0.0411 0.0320 0.202
B, regression coefficient; SE, standard error of B; CRP, C reactive protein;
SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; ECLAM,
European Consensus Lupus Activity Measurement; SDI, Systemic Lupus
International Collaborating Clinics/American College of Rheumatology
Damage Index.
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(0.44 (0.09) mmol/l, p=0.018). Figure 1 shows that the
percentage of patients with SLE with previous CVEs
increased across the tertiles of plasma ADMA levels
(p=0.023 for trend). Traditional risk factors for arterial
cardiovascular disease as well as ADMA levels were not
significantly associated with previous CVEs in multiple
regression analyses (data not shown).
Variables associated with plasma ADMA levels
Table 2 shows the results of univariate analyses.
In a stepwise multiple regression analysis a high SLEDAI
score, high modified SDI, high titre of anti-dsDNA anti-
bodies, and low serum HDL were significantly and indepen-
dently associated with plasma ADMA levels (table 3). The
Pearson correlation coefficient between the SLEDAI score
and ADMA levels was 0.503 (p,0.01).
DISCUSSION
The main finding of this study is that high plasma ADMA
levels were significantly associated with CVEs in patients
with SLE. In addition, ADMA levels were significantly
associated with measures of disease activity and organ
damage. As far as we know, this is the first study of the
association between ADMA levels and CVEs and disease
characteristics in patients with SLE.
The increased mean ADMA level in the group of patients
with SLE with a history of CVEs is in agreement with studies
in other patient groups at high risk of the development of
cardiovascular disease. Previous studies demonstrated
increased oxidative stress in SLE11 as well as raised plasma
levels of circulating oxidised low density lipoprotein in
patients with SLE with a history of CVEs.12 The major route
of ADMA elimination is degradation by the enzyme
dimethylarginine-dimethylaminohydrolase (DDAH), which
is very sensitive to oxidative stress.13 Reduced DDAH activity
by increased oxidative stress may thus contribute to
increased ADMA levels in SLE.
The second important finding of our study is the
association between ADMA levels and measures of disease
activity, especially a high titre of anti-dsDNA antibodies. This
observed association is in line with results of in vitro studies.
Anti-dsDNA antibodies were shown to be reactive with the
arginine-glycine-rich domains in recombinant heterogeneous
nuclear ribonucleoprotein A2 (hnRNP A2).9 Remarkably,
these domains are also preferred sites for the methylation of
arginine to ADMA by type 1 protein arginine methyltransfer-
ase (PRMT1).14 In the presence of anti-dsDNA, methylation
of hnRNP A2 by PRMT1 was increased to 3.5 times that of the
control level. Therefore, anti-dsDNA antibodies may be a
trigger for increased ADMA production by up regulating
methylation of arginine residues by PRMT1. Moreover, anti-
dsDNA monoclonal antibodies enhance the inflammatory
reaction by the release of proinflammatory cytokines from
mononuclear cells.15 These studies and our findings provide
scientific rationale for the hypothesis that anti-dsDNA
antibodies may have a role in the development of cardiovas-
cular disease in SLE by enhancing ADMA production and by
augmenting the inflammatory reaction.
Limitations of our study include the relatively small study
group and the cross sectional design. In our study, raised
ADMA levels and traditional risk factors for CVEs were not
independently associated with previous CVEs in multiple
regression analysis. This finding might be explained by the
relatively small study group and number of previous CVEs.
Furthermore, cross sectional data do not allow causality to be
established. A prospective study in a larger study group is
required to answer definitively the question of whether raised
ADMA levels are an independent risk factor for CVEs in
patients with SLE.
The association between ADMA levels and modified SDI
(excluding CVEs as an item) suggests that the nitric oxide
pathway might also be involved in the development of
damage in other organ systems in SLE. Further studies are
advocated to elucidate the role of the nitric oxide pathway
and its endogenous inhibitor ADMA in lupus pathogenesis
and the development of organ damage in SLE.
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Rituximab induces remission in stiff person syndrome
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of this article.
T
he first report of successful treatment with a monoclonal anti-B cell antibody may offer
new hope for patients with stiff person syndrome, a rare but ultimately fatal
autoimmune disease of the CNS.
Monoclonal antibody specific for B cells expressing CD20 antigen (rituximab) alleviated
severe symptoms when other treatments failed. It abolished intrathecal autoantibody
against glutamic acid decarboxylase (GAD), suggesting that the syndrome is a B cell
mediated autoimmune disease.
The 41 year old woman was an emergency admission in January 2004 with prolonged
painful muscle spasms in her neck and back and arms and legs, rendering her bedridden
and dependent on carers for months previously. She was taking baclofen and dantrolene
sodium daily, fentanyl patches twice weekly and parenteral diazepam up to 80 mg and
diamorphine up to 25 mg daily, providing subjective benefit.
The syndrome had been diagnosed in 2001. Various antispasmodic agents and disease
modifying treatments, including seven courses of intravenous immunoglobulin and courses
of cytotoxic drugs, tried since then had had no lasting success. Eventually, intrathecal
infusions of hydrocortisone produced transient improvement, in December 2003.
However, after just over two weeks of rituximab at 375 mg/m3, in January 2004, muscle
spasms started to subside, and the woman was able to sit up and shower herself for the first
time in two years. Testing in November 2003 showed intrathecal autoantibody to GAD, but
at 17 days’ treatment none was evident. One month after discharge her condition was stable
and she needed only small doses of oral benzodiazepine and analgesia until symptoms
recurred, at six weeks, when she was given further rituximab, with mycophenolate mofetil.
She improved again after 14 days and was discharged, remaining well after five months.
Symptomatic treatment relies on c-amino butyric acid (GABA) enhancing agents, but
previous treatments modifying immune response by reducing antibody to GAD, a rate
limiting enzyme in GABA synthesis, has had variable results.
m Baker MR, et al. Journal of Neurology, Neurosurgery, and Psychiatry 2005;76:999–1001.
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